300142 沃森生物
已收盘 10-19 15:00:00
资讯
新帖
简况
沃森生物（300142）10月14日主力资金净卖出1.12亿元
证券之星 · 10-15
沃森生物（300142）10月14日主力资金净卖出1.12亿元
沃森生物：公司本次向特定对象发行股票尚需通过深交所审核
证券之星 · 10-15
沃森生物：公司本次向特定对象发行股票尚需通过深交所审核
沃森生物(300142.SZ)：冻干带状疱疹病毒mRNA疫苗启动I期临床试验
智通财经 · 10-14
沃森生物(300142.SZ)：冻干带状疱疹病毒mRNA疫苗启动I期临床试验
沃森生物：冻干带状疱疹病毒mRNA疫苗正式启动I期临床试验
格隆汇 · 10-14
沃森生物：冻干带状疱疹病毒mRNA疫苗正式启动I期临床试验
沃森生物（300142）10月12日主力资金净卖出1.68亿元
证券之星 · 10-13
沃森生物（300142）10月12日主力资金净卖出1.68亿元
沃森生物（300142）10月9日主力资金净买入1.65亿元
证券之星 · 10-12
沃森生物（300142）10月9日主力资金净买入1.65亿元
沃森生物：公司已于9月23日向深交所报送了关于深交所对公司向特定对象发行股票事项的问询函的回函
证券之星 · 10-08
沃森生物：公司已于9月23日向深交所报送了关于深交所对公司向特定对象发行股票事项的问询函的回函
9月30日沃森生物涨5.49%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 09-30
9月30日沃森生物涨5.49%，招商国证生物医药指数(LOF)C基金重仓该股
沃森生物：公司向特定对象发行股票申请文件已获得深交所受理
证券之星 · 09-18
沃森生物：公司向特定对象发行股票申请文件已获得深交所受理
沃森生物：新型冠状病毒mRNA疫苗获药品注册证书
证券之星 · 09-18
沃森生物：新型冠状病毒mRNA疫苗获药品注册证书
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
证券之星 · 09-15
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
沃森生物：子公司新冠mRNA疫苗获批上市
格隆汇 · 09-10
沃森生物：子公司新冠mRNA疫苗获批上市
公司问答丨沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
格隆汇 · 09-08
公司问答丨沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
沃森生物：本次向特定对象发行股票尚需通过深交所审核
证券之星 · 09-08
沃森生物：本次向特定对象发行股票尚需通过深交所审核
沃森生物：本次收购完成后，公司持有玉溪沃森的股权比例进一步提升
证券之星 · 09-04
沃森生物：本次收购完成后，公司持有玉溪沃森的股权比例进一步提升
沃森生物：新型冠状病毒变异株mRNA疫苗正推进上市许可
证券之星 · 08-31
沃森生物：新型冠状病毒变异株mRNA疫苗正推进上市许可
沃森生物（300142）披露2026年半年度报告，8月31日股价下跌4.83%
证券之星 · 08-31
沃森生物（300142）披露2026年半年度报告，8月31日股价下跌4.83%
沃森生物：已建立mRNA疫苗研发到商业化生产的完整能力
证券之星 · 08-31
沃森生物：已建立mRNA疫苗研发到商业化生产的完整能力
沃森生物(300142)6月30日股东户数13.1万户，较上期增加10.56%
证券之星 · 08-29
沃森生物(300142)6月30日股东户数13.1万户，较上期增加10.56%
图解沃森生物中报：第二季度单季净利润同比下降239.42%
证券之星 · 08-29
图解沃森生物中报：第二季度单季净利润同比下降239.42%
公司概况
公司名称：
云南沃森生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2010-11-12
主营业务：
云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是疫苗产品。
发行价格：
95.00
{"stockData":{"symbol":"300142","market":"SZ","secType":"STK","nameCN":"沃森生物","latestPrice":12.85,"timestamp":1792393380000,"preClose":13.27,"halted":0,"volume":67315901,"delay":0,"changeRate":-0.0317,"floatShares":1578000000,"shares":1599000000,"eps":0.1181,"marketStatus":"已收盘","change":-0.42,"latestTime":"10-19 15:00:00","open":13,"high":13.15,"low":12.66,"amount":865000000,"amplitude":0.0369,"askPrice":12.85,"askSize":334,"bidPrice":12.84,"bidSize":912,"shortable":0,"etf":0,"ttmEps":0.1181,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":5,"adr":0,"adjPreClose":13.27,"symbolType":"stock","openAndCloseTimeList":[[1792373400000,1792380600000],[1792386000000,1792393200000]],"highLimit":14.6,"lowLimit":11.94,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1599348541,"isCdr":false,"pbRate":3.04,"roa":"--","peRate":108.806097,"roe":"0.74%","epsLYR":0.1111,"committee":0.179424,"marketValue":20552000000,"turnoverRate":0.0427,"status":1,"floatMarketCap":20275000000},"requestUrl":"/m/hq/s/300142/wiki","defaultTab":"wiki","newsList":[{"id":"2675037936","title":"沃森生物（300142）10月14日主力资金净卖出1.12亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675037936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675037936?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:14","pubTimestamp":1792026899,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月14日收盘，沃森生物报收于13.35元，下跌5.18%，换手率5.15%，成交量81.19万手，成交额11.03亿元。近5日资金流向一览见下表：沃森生物融资融券信息显示，融资方面，当日融资买入1.31亿元，融资偿还1.03亿元，融资净买入2830.61万元，连续3日净买入累计1.1亿元。沃森生物主营业务：从事人用疫苗等生物技术药集研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500008226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","300142","BK0046","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675721375","title":"沃森生物：公司本次向特定对象发行股票尚需通过深交所审核","url":"https://stock-news.laohu8.com/highlight/detail?id=2675721375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675721375?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:36","pubTimestamp":1792024569,"startTime":"0","endTime":"0","summary":"公司已于9月23日向深交所报送了关于深交所对公司向特定对象发行股票事项的问询函的回函并同步在巨潮资讯网披露了回函内容，同时按照相关规定对募集说明书等发行申请文件的内容进行了更新和披露，具体内容请查阅公司在巨潮资讯网披露的相关公告。公司本次向特定对象发行股票尚需通过深交所审核，并获得中国证监会同意注册的批复后方可实施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500007237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300142","BK0239","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675034494","title":"沃森生物(300142.SZ)：冻干带状疱疹病毒mRNA疫苗启动I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2675034494","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675034494?lang=zh_cn&edition=full","pubTime":"2026-10-14 20:34","pubTimestamp":1791981274,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沃森生物(300142.SZ)发布公告，由公司子公司北京沃森创新生物技术有限公司、云南疫苗实验室有限公司、玉溪沃森生物技术有限公司与复旦大学、上海蓝鹊生物医药有限公司(简称“蓝鹊生物”)联合研发的冻干带状疱疹病毒mRNA疫苗已完成I期临床试验准备工作，于今日召开了I期临床试验启动会，正式启动I期临床试验工作。该疫苗启动I期临床试验是本疫苗研发过程中取得的阶段性进展，公司将积极推动疫苗的临床研究工作，若该疫苗研发成功，将进一步丰富公司在mRNA疫苗领域及成人疫苗领域的产品布局，为公司长远持续稳健发展奠定坚实基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0070","BK0077","300142","BK0046","BMED","MRNY","BK0239","MRNX","PSYK","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675731046","title":"沃森生物：冻干带状疱疹病毒mRNA疫苗正式启动I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2675731046","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675731046?lang=zh_cn&edition=full","pubTime":"2026-10-14 17:47","pubTimestamp":1791971252,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK0046","300142","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675389719","title":"沃森生物（300142）10月12日主力资金净卖出1.68亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675389719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675389719?lang=zh_cn&edition=full","pubTime":"2026-10-13 09:19","pubTimestamp":1791854390,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月12日收盘，沃森生物报收于14.05元，下跌4.75%，换手率6.66%，成交量105.16万手，成交额15.12亿元。近5日资金流向一览见下表：沃森生物融资融券信息显示，融资方面，当日融资买入1.8亿元，融资偿还1.14亿元，融资净买入6569.97万元，连续3日净买入累计1.44亿元。沃森生物主营业务：从事人用疫苗等生物技术药集研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300008591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0239","BK0077","BK0046","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674847372","title":"沃森生物（300142）10月9日主力资金净买入1.65亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674847372","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674847372?lang=zh_cn&edition=full","pubTime":"2026-10-12 09:07","pubTimestamp":1791767271,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月9日收盘，沃森生物报收于14.75元，上涨4.76%，换手率9.4%，成交量148.34万手，成交额21.2亿元。近5日资金流向一览见下表：沃森生物融资融券信息显示，融资方面，当日融资买入1.92亿元，融资偿还1.72亿元，融资净买入1954.35万元。沃森生物主营业务：从事人用疫苗等生物技术药集研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200002910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0239","BK0070","BK0046","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673027652","title":"沃森生物：公司已于9月23日向深交所报送了关于深交所对公司向特定对象发行股票事项的问询函的回函","url":"https://stock-news.laohu8.com/highlight/detail?id=2673027652","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673027652?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:42","pubTimestamp":1791448936,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物10月08日在投资者关系平台上答复投资者关心的问题。如此儿戏的定增方案，限定价格限定发行股票数，设置上限有没有抑制股价沃森生物回复：尊敬的投资者，您好！公司已于9月23日向深交所报送了关于深交所对公司向特定对象发行股票事项的问询函的回函并同步在巨潮资讯网披露了回函内容，同时按照相关规定对募集说明书等发行申请文件的内容进行了更新和披露，具体内容请查阅公司在巨潮资讯网披露的相关公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800021366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300142","BK0239","BK0077","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671274469","title":"9月30日沃森生物涨5.49%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671274469","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671274469?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:38","pubTimestamp":1790757521,"startTime":"0","endTime":"0","summary":"证券之星消息，9月30日沃森生物涨5.49%，收盘报14.23元，换手率9.73%，成交量153.56万手，成交额21.83亿元。重仓沃森生物的前十大公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共14家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000026014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399441","BK0077","161726","300142","BK0046","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668292925","title":"沃森生物：公司向特定对象发行股票申请文件已获得深交所受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2668292925","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668292925?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:48","pubTimestamp":1789735698,"startTime":"0","endTime":"0","summary":"公司于2026年8月27日收到深圳证券交易所出具的《关于受理云南沃森生物技术股份有限公司向特定对象发行股票申请文件的通知》，本次发行项目的申请文件已获得深交所受理。鉴于本次发行事项尚在持续推进中，本次向特定对象发行股票事项最终能否通过深交所审核，并获得中国证监会同意注册的批复及其时间尚存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800034929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","BK0046","BK0239","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668460719","title":"沃森生物：新型冠状病毒mRNA疫苗获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2668460719","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668460719?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:21","pubTimestamp":1789719668,"startTime":"0","endTime":"0","summary":"公司基于mRNA平台技术策略迭代开发的新型冠状病毒mRNA疫苗已于2026年9月10日收到《药品注册证书》。另有呼吸道合胞病毒mRNA疫苗、冻干带状疱疹病毒mRNA疫苗已获得《药物临床试验批准通知书》，正在开展I期临床试验准备相关工作。关于公司mRNA技术平台及具体产品的研发进展，请您查阅公司在巨潮资讯网披露的定期报告及相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800024134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0077","BK0070","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667941766","title":"沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2667941766","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667941766?lang=zh_cn&edition=full","pubTime":"2026-09-15 08:27","pubTimestamp":1789432024,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)09月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司九价hpv疫苗数据整理要多久才能整理好提交审批沃森生物回复：尊敬的投资者，您好！感谢您对公司的关注。公司九价HPV疫苗目前处于III期临床研究阶段，公司将按照国家对于疫苗注册临床试验的有关程序和要求推进在研疫苗产品的相关工作，有关信息请持续关注公司后续披露的公告和定期报告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500006267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300142","BK0239","159646","BK0077","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666659892","title":"沃森生物：子公司新冠mRNA疫苗获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2666659892","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666659892?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:50","pubTimestamp":1789041059,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300142","BK0046","BK0070","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665752328","title":"公司问答丨沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2665752328","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665752328?lang=zh_cn&edition=full","pubTime":"2026-09-08 15:41","pubTimestamp":1788853315,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0046","BK0070","159646","BK0077","BK0239","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665344548","title":"沃森生物：本次向特定对象发行股票尚需通过深交所审核","url":"https://stock-news.laohu8.com/highlight/detail?id=2665344548","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665344548?lang=zh_cn&edition=full","pubTime":"2026-09-08 11:33","pubTimestamp":1788838396,"startTime":"0","endTime":"0","summary":"2026年8月27日，公司收到深圳证券交易所出具的《关于受理云南沃森生物技术股份有限公司向特定对象发行股票申请文件的通知》，本次发行项目的申请文件已获得深交所受理。公司本次向特定对象发行股票尚需通过深交所审核，并获得中国证监会同意注册的批复后方可实施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800015110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","BK0239","300142","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664387386","title":"沃森生物：本次收购完成后，公司持有玉溪沃森的股权比例进一步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2664387386","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664387386?lang=zh_cn&edition=full","pubTime":"2026-09-04 11:37","pubTimestamp":1788493056,"startTime":"0","endTime":"0","summary":"公司收购玉溪沃森少数股东股权事项的相关情况，公司已在巨潮资讯网披露的公告中进行说明，具体请以公司公告为准。本次收购完成后，公司持有玉溪沃森的股权比例进一步提升，有利于增强公司对子公司的管控和资源整合效率，提高玉溪沃森决策效率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400016764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0239","BK0077","BK0070","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663053850","title":"沃森生物：新型冠状病毒变异株mRNA疫苗正推进上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2663053850","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663053850?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:51","pubTimestamp":1788180697,"startTime":"0","endTime":"0","summary":"公司基于已构建的mRNA技术平台迭代开发的新型冠状病毒变异株mRNA疫苗正积极推进申请上市许可的药品注册相关工作；呼吸道合胞病毒mRNA疫苗、冻干带状疱疹病毒mRNA疫苗均已获得《药物临床试验批准通知书》，正在开展I期临床试验准备相关工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100034396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300142","BK0239","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079198","title":"沃森生物（300142）披露2026年半年度报告，8月31日股价下跌4.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079198","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663079198?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:37","pubTimestamp":1788169029,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，沃森生物报收于13.59元，较前一交易日下跌4.83%，最新总市值为217.35亿元。该股当日开盘13.87元，最高14.06元，最低13.34元，成交额达20.36亿元，换手率为9.49%。公司于近日披露《2026年半年度报告》。公告显示，本报告期营业收入为834,215,184.81元，较上年同期下降27.72%；归属于上市公司股东的净利润为54,192,194.54元，同比增长25.56%；归属于上市公司股东的扣除非经常性损益的净利润为94,944,847.48元，同比增长233.81%；经营活动产生的现金流量净额为173,917,286.99元，同比增长49.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100024148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300142","BK0077","BK0070","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663209130","title":"沃森生物：已建立mRNA疫苗研发到商业化生产的完整能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2663209130","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663209130?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:04","pubTimestamp":1788159856,"startTime":"0","endTime":"0","summary":"公司持续开展基于mRNA平台技术的疫苗开发，已经建立了从研发、中试到商业化生产的完整能力，并在相关产品的研发上取得了阶段性进展。关于公司mRNA疫苗的具体技术细节、研发进度及生产布局，请参阅公司在巨潮资讯网披露的定期报告及相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100014766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300142","BK0239","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663966012","title":"沃森生物(300142)6月30日股东户数13.1万户，较上期增加10.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663966012","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663966012?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:16","pubTimestamp":1787995001,"startTime":"0","endTime":"0","summary":"证券之星消息，近日沃森生物披露，截至2026年6月30日公司股东户数为13.1万户，较3月31日增加1.25万户，增幅为10.56%。在生物制品行业个股中，沃森生物股东户数高于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.54万户。从股价来看，2026年3月31日至2026年6月30日，沃森生物区间涨幅为5.86%，在此期间股东户数增加1.25万户，增幅为10.56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300142","BK0070","BK0046","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013339","title":"图解沃森生物中报：第二季度单季净利润同比下降239.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013339","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663013339?lang=zh_cn&edition=full","pubTime":"2026-08-29 03:24","pubTimestamp":1787945058,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物2026年中报显示，上半年度公司主营收入8.34亿元，同比下降27.72%；归母净利润5419.22万元，同比上升25.56%；扣非净利润9494.48万元，同比上升233.81%；其中2026年第二季度，公司单季度主营收入3.9亿元，同比下降43.58%；单季度归母净利润-5648.48万元，同比下降239.42%；单季度扣非净利润-1871.65万元，同比下降146.87%；负债率30.18%，投资收益-7.5万元，财务费用1272.43万元，毛利率68.79%。财报数据概要请见下图:本文数据来源于沃森生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900007366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792446642795,"stockEarnings":[{"period":"1week","weight":-0.0854},{"period":"1month","weight":-0.0346},{"period":"3month","weight":-0.0586},{"period":"6month","weight":0.057},{"period":"1year","weight":0.1486},{"period":"ytd","weight":0.1928}],"compareEarnings":[{"period":"1week","weight":-0.0175},{"period":"1month","weight":-0.0463},{"period":"3month","weight":-0.0345},{"period":"6month","weight":-0.0914},{"period":"1year","weight":-0.0283},{"period":"ytd","weight":-0.0599}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南沃森生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"130959人(较上一季度增加10.56%)","perCapita":"12048股","listingDate":"2010-11-12","address":"云南省昆明市五华区高新区科新路395号","registeredCapital":"159934万元","survey":" 云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是疫苗产品。","listedPrice":95},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沃森生物,300142,沃森生物股票,沃森生物股票老虎,沃森生物股票老虎国际,沃森生物行情,沃森生物股票行情,沃森生物股价,沃森生物股市,沃森生物股票价格,沃森生物股票交易,沃森生物股票购买,沃森生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}